Vera Therapeutics' Kidney Disease Drug Shows Promising 46% Proteinuria Reduction in Phase 3 Trial
Vera Therapeutics announced positive Phase 3 trial results for its kidney disease drug atacicept, which significantly reduced proteinuria in patients with IgA nephropathy, supporting a potential FDA submission later this year.